

Lymphoma Committee

Leadership

Chair: Jonathan W. Friedberg, MD
 Vice-Chair: Sonali M. Smith, MD
 Executive Officer: Susan M. O'Brien, MD
 Statisticians: Michael LeBlanc, PhD
 Hongli Li, MS

Scientific Leadership

Translational Medicine: Alexey Danilov, MD, PhD
 Radiation Oncology: Louis S. Constine, MD
 Imaging: Lawrence H. Schwartz, MD
 Pathology: Joo Y. Song, MD
 Early Therapeutics: Nasheed Mohammad Hossain, MD

Designates

Cancer Control: Hayder Saeed, MD
 Digital Engagement: Mazyar Shadman, MD
 Veterans Affairs: Helen Ma, MD
 Data Coordinators: Gabi Herbert
 Oncology Research Professionals:
 CRA: Erin M. Cebula, MPH
 Nurse: TBD
 Patient Advocate: Hildy Dillon, MPH
 Pharmaceutical Science: Holly O. Chan, PharmD
 Martina Fraga, PharmD
 Protocol Project Manager: Katarina Gasic
 Clinical Trials Program Manager: Crystal Miwa

Time/Location

Saturday, May 13, 2023 9:30 am - 11:30 am

Room: Grand Ballroom B (Street Level)

Agenda

9:30 - 9:35 am	Welcome - Jonathan Friedberg, MD & Sonali Smith, MD
9:35 - 9:55 am	Impact of SWOG trials: Katherine Albert, PhD, Patient advocate
9:55 - 10:15 am	S2114 launch - Dr. Hess
10:15 - 10:35 am	S2207 launch - Drs. Amengual & Reagan
10:35 - 10:45 am	S0016 long-term follow-up update - Dr. Shadman
10:45 - 10:55 am	COG Hodgkin early stage launch - Dr. Hu
10:55 - 11:30 am	Ongoing study updates
a.	S1918 Dr. Brem
b.	S1608 Dr. Barr
c.	ANHL1931: Dr. Kamdar

- d. EA4151: Dr. Till
- e. EA4181: Dr. Spurgeon
- f. A051701: pending speaker
- g. S1925 (CLL): Dr. Stephens

Proposed Studies

S2207, "Randomized phase II study of the addition of Targeted therapeutic agents to tafasitamab-based therapy in non-transplant-eligible patients with Relapsed/refractory Large B-cell Lymphoma." Drs. Amengual and Reagan.

S2308, "Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma." Drs. Ghosh and Friedberg.

Active Studies

S1608, "Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma." Drs. Barr and Burack. Activated: 8/10/17.

S1918, "A Phase II/III Randomized Study of R-miniCHOP With or Without CC-486 (Oral Azacytidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements." Drs. Brem and Smith. Activated: 3/19/21.

S2114, "A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma." Drs. Hess and Hossain. Activated: 2/23/23.

CTSUA051701, "Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas." Dr. Abramson. SWOG Champion: Dr. Vallurupalli. Activated: 8/7/19. Temporarily closed: 8/2/21.

CTSUEA4151, "A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission. Dr. Fenske. SWOG Champion: Dr. Till. Activated: 8/29/17.

CTSUEA4181, "A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CA-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A)

Lymphoma Committee

Accrual from trial opening through 12/31/2022 by Institution and Study

	S1608	S1826	S1918	A051301	A051701	ANHL1931	E4412	EA4151	EA4181
Ascension Providence Hosp - Southfield	-	5	-	-	-	-	-	-	-
Banner U Med Ctr - Tucson	2	-	-	1	-	-	-	1	2
Baptist Mem Hlth Care/Mid South MU NCORP	-	3	-	-	-	-	-	-	-
Baylor College of Med/Dan L Duncan CCC	-	-	-	1	-	-	-	-	-
Boston Med Ctr	-	3	-	-	-	-	-	-	-
CWRU Case CCC LAPS	-	-	-	-	8	-	-	12	12
Ca Res Consort of W Mich NCORP	3	13	-	-	-	-	-	-	-
Ca Res for the Ozarks NCORP	1	5	-	-	-	-	-	-	-
Ca Res of Wisconsin and N Mich Consort	-	2	-	-	-	-	-	-	-
Carle CC NCORP	1	3	-	-	-	-	-	-	-
City of Hope CCC	8	21	2	1	-	1	-	18	-
Columbia U MU NCORP	-	2	2	-	-	-	1	-	-
Columbus NCORP	1	2	-	-	-	-	-	-	-
CommonSpirit Hlth Res Inst	-	4	-	-	-	-	-	-	-
Essentia Hlth NCORP	-	3	-	-	-	-	-	-	-
Fred Hutchinson Ca Res Ctr LAPS	-	-	-	-	-	-	-	13	-
Georgia Cares MU NCORP	-	6	1	-	-	-	-	-	-
Gulf South MU NCORP	-	-	2	-	-	-	-	-	-
Heartland Ca Res NCORP	1	20	-	-	-	-	-	-	-
Henry Ford Hosp	-	8	-	-	2	-	-	-	-
Kaiser Permanente NCORP	2	11	1	-	-	-	11	-	12
King Faisal Specialist Hosp and Res Centre	-	-	-	4	-	-	-	-	-
Loyola U Med Ctr	-	8	-	-	-	-	-	3	-
Med U South Carolina MU NCORP	2	19	3	-	3	-	-	2	-
Michigan Ca Res Consort NCORP	1	6	3	-	-	-	-	-	-
Moffitt CC	-	15	-	-	-	-	-	-	-
Montana Ca Consort NCORP	-	8	-	-	-	-	-	-	-
NCORP Carolinas (Prisma Hlth NCORP)	-	11	-	-	-	-	-	2	-
Nevada Ca Res Foundation NCORP	-	2	-	-	-	-	1	-	-
Northwell Hlth NCORP	-	-	-	-	1	-	-	-	-

Lymphoma Committee

Accrual from trial opening through 12/31/2022 by Institution and Study

	S1608	S1826	S1918	A051301	A051701	ANHL1931	E4412	EA4151	EA4181
Northwestern U LAPS	1	-	-	-	-	1	-	-	-
Oregon Hlth and Science U	-	4	-	-	2	-	-	5	5
Pacific Ca Res Consort NCORP	-	7	-	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	-	6	-	-	-	-	-	-	-
UC Davis CCC LAPS	-	18	-	-	4	-	-	-	-
UC Irvine Hlth/Chao Family CCC	-	4	1	-	-	1	-	-	-
UC San Diego Moores CC	-	8	-	-	-	-	-	1	-
U Alabama Birm / Deep South RC LAPS	-	12	-	-	3	-	7	5	-
U Arkansas for Med Sciences	-	1	-	-	-	-	-	-	-
U Cincinnati CC-UC Med Ctr	-	9	-	-	-	-	-	2	2
U Colorado CC LAPS	-	4	-	1	-	-	-	-	-
U Kansas CC - MCA Rural MU NCORP	-	-	-	-	-	-	-	-	1
U Kentucky/Markey CC	-	2	-	-	-	-	-	1	-
U Michigan CCC LAPS	-	-	-	-	-	-	-	1	-
U Mississippi Med Ctr	-	1	-	-	-	-	-	-	-
U Rochester LAPS	13	33	-	3	11	2	-	10	16
U Texas HSC at San Antonio	-	17	-	-	-	-	-	11	-
U Texas MD Anderson CC LAPS	3	34	-	-	-	-	-	-	-
U Utah - Huntsman Ca Inst LAPS	1	14	1	-	-	-	-	14	12
Upstate Carolina NCORP	1	7	-	-	-	-	-	-	-
Wayne State U - Karmanos Ca Inst LAPS	-	4	-	1	-	-	-	1	6
Wisconsin NCORP	-	11	-	-	-	-	-	-	-
Yale U - Yale CC LAPS	-	7	-	-	-	-	-	4	-
ALLIANCE	15	134	21	-	-	-	-	-	-
CCTG	-	30	-	-	-	-	-	-	-
COG	-	313	-	-	-	-	-	-	-
ECOG-ACRIN	5	83	8	-	-	-	-	-	-
NRG	11	51	3	-	-	-	-	-	-
Total	72	994	48	12	34	5	20	106	68